Status:

TERMINATED

Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy

Lead Sponsor:

ATGen Canada Inc

Conditions:

Immunity, Innate

Prostatic Neoplasm

Eligibility:

MALE

18+ years

Phase:

NA

Brief Summary

This study will look at measuring the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in subjects being screened for prostate cancer using prostate biopsy.

Detailed Description

The NK Vue diagnostic test for natural killer cell activity uses the principle of stimulation of whole blood with a proprietary cytokine followed by the quantitative detection of interferon-gamma usin...

Eligibility Criteria

Inclusion

  • Male aged ≥ 18 years old
  • Able to read and sign an approved informed consent form
  • Soon to be undergoing a needle prostate biopsy for suspected prostate cancer; patients with a history of prior biopsy are not excluded provided the biopsy was negative
  • All prior and current recorded PSA levels are \< 11 ng/mL (minimum of 2 values must be available)
  • Digital Rectal Exam performed or scheduled to be performed prior to biopsy

Exclusion

  • Any other established malignancy with the exception of basal cell carcinoma
  • At time of blood collection, an active infection (eg bacterial, viral etc.) as declared by the patient
  • Chronic inflammatory condition requiring anti-inflammatory treatment such as rheumatoid arthritis, Crohn's or ulcerative colitis, Lupus or any connective tissue condition which, in the opinion of the investigator, might affect the immune response
  • Presently taking any of the following classes of medications on a regular basis:
  • 5-alpha reductase inhibitors
  • Anti-inflammatories, with the exception of low dose (81 mg) acetylsalicylic acid
  • Anti-androgens
  • Testosterone replacement therapy

Key Trial Info

Start Date :

April 4 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 20 2019

Estimated Enrollment :

84 Patients enrolled

Trial Details

Trial ID

NCT03242265

Start Date

April 4 2017

End Date

March 20 2019

Last Update

July 5 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Princess Margaret Cancer Center, University Health Network

Toronto, Ontario, Canada, M5G 1Z5